Afatinib is a drug that targets NSCLC with specific EGFR mutations, like the 19th exon deletion or the 21st exon L858R mutation. It’s designed to stop EGFR from sending those signals. You can get it in doses of 20, 30, or 40 milligrams, all in film-coated tablets.
The usual dose is 40 milligrams, taken once a day on an empty stomach. It comes in bottles with 30 tablets each.
